Methylprednisolone hemisuccinate
- Generic Name
- Methylprednisolone hemisuccinate
- Brand Names
- Solu-medrol
- Drug Type
- Small Molecule
- Chemical Formula
- C26H34O8
- CAS Number
- 2921-57-5
- Unique Ingredient Identifier
- 5GMR90S4KN
- Background
A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
- Associated Conditions
- Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis
- Associated Therapies
- Palliative Treatment
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
Phase 3
Active, not recruiting
- Conditions
- Childhood Idiopathic Nephrotic Syndrome
- Interventions
- Drug: ObinutuzumabDrug: MMFDrug: PrednisoneDrug: MethylprednisoloneDrug: Acetaminophen/ ParacetamolDrug: Diphenhydramine Hydrochloride
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT05627557
- Locations
- 🇺🇸
Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸Children's Healthcare of Atlanta Center for Advanced Pediatrics, Atlanta, Georgia, United States
🇺🇸Nicklaus Children's Hospital, Miami, Florida, United States
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Phase 2
Recruiting
- Conditions
- Lupus Nephritis
- Interventions
- Drug: PlaceboDrug: ObinutuzumabDrug: Mycophenolate MofetilDrug: Acetaminophen/paracetamolDrug: Diphenhydramine hydrochloride (HCl)Drug: MethylprednisoloneDrug: Prednisone
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT05039619
- Locations
- 🇺🇸
Cohen Children's Medical Center of New York, Queens, New York, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇧🇷Centro de Pesquisa São Lucas, Campinas, São Paulo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath